The UK and US have announced a significant commercial pact that will keep zero duties on British drug exports entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to boost expenditure on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these key goods will remain at zero for a timeframe of 36 months.
This agreement is in response to earlier statements to significantly raise tariffs on branded drug imports, with increases floated up to double the cost.
"This arrangement between the United Kingdom reinforces the global environment for innovative medicines and brings long-overdue fairness to transatlantic drug exports," a statement said.
Trade Importance
Medicines represent one of the the United Kingdom's largest exports to the America, which is clearly the primary buyer for large British pharmaceutical firms.
Trade data indicate that in the 12 months to the end of September, the UK shipped medicines valued at over eleven billion pounds to the US. This value made up a significant portion of British export trade in that period.
"This deal protects employment, boosts investment and facilitates the UK to become a global hub for life sciences," a minister remarked.
Key British Pledges
The deal involves several notable changes from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to double total health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The amount drug companies must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, refunds exceeded twenty percent.
Broader Context
The deal follows a long-running dispute between the sector and the British authorities over spending levels and regulatory access.
These tensions were intensified by claims that US patients were paying several times more for the same drugs than patients in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been directed toward US facilities.
A senior figure publicly accepted that the NHS must spend more on treatments, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
